Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
暂无分享,去创建一个
[1] Ami C Bautista,et al. Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment. , 2010, Bioanalysis.
[2] J. Vielmetter,et al. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. , 2006, Clinical immunology.
[3] N. Barois,et al. Receptor-mediated endocytosis of immune complexes in rat liver sinusoidal endothelial cells is mediated by FcgammaRIIb2. , 2007, Hepatology.
[4] Patrick G. Swann,et al. Considerations for the development of therapeutic monoclonal antibodies. , 2008, Current opinion in immunology.
[5] A. Millonig,et al. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study , 2009, Multiple sclerosis.
[6] N. Barois,et al. Receptor‐mediated endocytosis of immune complexes in rat liver sinusoidal endothelial cells is mediated by FcγRIIb2 , 2007 .
[7] Jean W. Lee,et al. Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand. , 2010, Journal of pharmaceutical and biomedical analysis.
[8] A. Mire-Sluis,et al. Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation. , 2010, Biologicals : journal of the International Association of Biological Standardization.
[9] B. Meibohm,et al. Population Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.
[10] Eugen Koren,et al. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. , 2005, Journal of immunological methods.
[11] M. Tabrizi,et al. Preclinical and clinical safety of monoclonal antibodies. , 2007, Drug discovery today.
[12] Thomas Singer,et al. The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.
[13] Robin Thorpe,et al. Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[14] Bruce N. Rehlaender,et al. Antibodies as Carrier Proteins , 1998, Pharmaceutical Research.
[15] A. Rathore,et al. Quality by design for biopharmaceuticals , 2009, Nature Biotechnology.
[16] Heather Myler,et al. Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development , 2011, The AAPS Journal.
[17] An Carbonez,et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.
[18] Yuan-Tsong Chen,et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease , 2011, Genetics in Medicine.
[19] L. Gibiansky,et al. Population PK and IgE Pharmacodynamic Analysis of a Fully Human Monoclonal Antibody Against IL4 Receptor , 2011, Pharmaceutical Research.
[20] B. Meibohm,et al. Pharmacokinetic aspects of biotechnology products. , 2004, Journal of pharmaceutical sciences.
[21] Meina Liang,et al. Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. , 2007, Assay and drug development technologies.
[22] V. Quarmby,et al. Clinical immunogenicity specificity assessments: a platform evaluation. , 2011, Journal of pharmaceutical and biomedical analysis.
[23] N. Chirmule,et al. Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects , 2010, Annals of Hematology.
[24] B. Dijkmans,et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept , 2010, Annals of the rheumatic diseases.
[25] B. Dijkmans,et al. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation , 2006, Annals of the rheumatic diseases.
[26] G. Walsh. Pharmaceutical Biotechnology: Concepts and Applications , 2007 .
[27] K. Knight,et al. Somatic hypermutation: mutations 3' of rabbit VDJ H-chain genes. , 1997, Journal of immunology.
[28] Arunan Kaliyaperumal,et al. Comparing ELISA and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of Panitumumab , 2007, The Journal of Immunology.
[29] S. Quataert,et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S , 1995, Clinical and diagnostic laboratory immunology.
[30] Viswanath Devanarayan,et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. , 2011, Journal of pharmaceutical and biomedical analysis.
[31] R Seitz,et al. Taking immunogenicity assessment of therapeutic proteins to the next level. , 2011, Biologicals : journal of the International Association of Biological Standardization.
[32] M. Allez. L’immunisation contre l’infliximab, associée à des réactions d’intolérance et à une perte d’efficacité, peut être prévenue par l’utilisation d’immunosuppresseurs , 2004 .
[33] Jos H. Beijnen,et al. Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.
[34] D. Salinger,et al. Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies , 2011, Clinical pharmacokinetics.
[35] C. Gegg,et al. Ligand-Binding Mass Spectrometry to Study Biotransformation of Fusion Protein Drugs and Guide Immunoassay Development: Strategic Approach and Application to Peptibodies Targeting the Thrombopoietin Receptor , 2010, The AAPS Journal.
[36] Huub Schellekens,et al. Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.
[37] H. Mandel,et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. , 2010, Molecular genetics and metabolism.
[38] M. Carcao,et al. Current and future approaches to inhibitor management and aversion. , 2006, Seminars in thrombosis and hemostasis.
[39] Viswanath Devanarayan,et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. , 2008, Journal of pharmaceutical and biomedical analysis.
[40] George Scott,et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.
[41] B. Klein,et al. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. , 1995, Blood.
[42] R. Keenan,et al. Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort , 2009, Journal of thrombosis and haemostasis : JTH.
[43] E. D. De Jong,et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. , 2010, Archives of dermatology.
[44] B. Dijkmans,et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. , 2011, JAMA.